The European League Against Rheumatism (EULAR) recommends that in patients with rheumatoid arthritis (RA), methotrexate (MTX) should be prescribed first if there are no contraindications because the drug is effective alone and may be more effective when used in combination with other conventional synthetic disease-modifying anti-rheumatic drugs (cs-DMARDs) or biological DMARDs (b-DMARDs).1,2) Combination therapies comprising b-DMARDs - especially tumor necrosis factor inhibitors - and MTX have been shown to be more efficacious than b-DMARD monotherapies.3,4) Indeed, the more b-DMARDs are extensively used, the more MTX is recognized as a useful therapy. However, MTX has several serious side effects such as myelosuppression, interstitial pneumonia, and infection; hence, caution must be exercised when using it, particularly with highly efficacious b-DMARDs.
Monotherapy with the b-DMARDtocilizumab (TCZ), a humanized monoclonal antibody against the interleukin (IL)-6 receptor that functions by inhibiting interaction between IL-6 and the IL-6 receptor, reportedly affords more evident repair of existing bone erosions than combination therapy with MTX andthe most commonly used b-DMARD, adalimumab.5) Furthermore, the effectiveness of TCZ monotherapy was reported as comparable to that of TCZ and DMARD combination therapy, although the observation period was as short as 24 weeks.6) Meanwhile, consensus is lacking on whether TCZ used in combination with MTX is useful, although the utility of TCZ used in combination with MTX, and as a monotherapy, has been documented.7)
Recently, two milestone studies compared the efficacy of TCZ+MTX combination therapy and TCZ monotherapy. The first study was the ACT-RAY study, which compared TCZ+MTX combination therapy and TCZ monotherapy in patients with RA with an inadequate response (IR) to MTX. Clinical and radiographic findings suggested that both treatments are effective and comparable, indicating that combination therapy does not afford a significant improvement.8) In the second study, termed the SURPRISE study, TCZ+MTX combination therapy was compared with TCZ monotherapy switched from MTX in patients with RA with an IR to MTX. The combination therapy suppressed inflammation more rapidly than TCZ monotherapy, indicating the superior efficacy of the combination therapy based on both clinical and radiographic findings.9)
However, there are some notable fundamental differences between these studies. For example, the disease duration in the SURPRISE study was 3.6 to 3.8 years, which was shorter than that in the ACT-RAY study (8.2 to 8.3 years). Moreover, conventional DMARDs were administered to patients with a disease activity score in 28 joints (DAS28) of > 3.2 at week 24 in the ACT-RAY study, which complicated the comparison between TCZ monotherapy and TCZ+MTX combination therapy.
Nevertheless, both studies reported that a combination including MTX increases the incidence of adverse events, such as gastrointestinal, respiratory, thoracic, and mediastinal disorders as well as laboratory test abnormalities. In both studies, the goal was to determine the necessity of using MTX in combination with TCZ to achieve remission in patients with RA. Although achieving clinical remission is the target of RA treatment,10) prolonged treatment with MTX necessitates close monitoring for possible complications, such as infectious diseases, lung disorders, bone marrow suppression, renal disorders, liver disorders,11) and lymphoproliferative diseases. Hence, the aim of the present study was to evaluate the feasibility of MTX discontinuation after achieving RA remission for the safety of patients treated with TCZ+MTX combination therapy.